Sanofi Initiates Phase 2 HIMALAYA Study of SAR443820 in …
May 3, 2022 · Sanofi has initiated dosing of SAR443820, its central nervous system penetrant small-molecule RIPK1 inhibitor, in the phase 2 HIMALAYA study (NCT05237284) in …
Our Neurology R&D: Neurological Disease Research - Sanofi
Mar 15, 2021 · Sanofi R&D teams are developing innovative new medicines that are built on patient insights and expertise in disease biology, and enabled by pioneering technologies such …
ALS drug from Denali, Sanofi falls short in mid-stage study
Feb 16, 2024 · An experimental drug being developed by Denali Therapeutics and partner Sanofi for ALS failed to meet its goal in a Phase 2 trial, the biotechnology company disclosed …
Sanofi stumbles in HIMALAYA trial, chalking up phase 2 ALS fail
Feb 20, 2024 · The phase 2 study randomized 305 people with amyotrophic lateral sclerosis (ALS) to receive SAR443820, a RIPK1 inhibitor also known as DNL788, or placebo orally …
Denali makes ALS play, hustling Sanofi-partnered drug into phase …
Oct 7, 2021 · Denali Therapeutics has set out its play for the amyotrophic lateral sclerosis (ALS) market, revealing early-phase data on one asset and plans to move a Sanofi-partnered …
Sanofi and Denali to Develop Small Molecules to Treat ALS, Other...
Nov 6, 2018 · Denali Therapeutics and Sanofi have joined efforts to develop small molecule inhibitors of the RIPK1 enzyme, a new class of potential therapeutic agents for a range of …
ALS Agent SAR443820 Shows High CNS Penetration, Promising …
Apr 25, 2023 · Findings from the first-in-human phase 1 study assessing SAR443820 (Sanofi), an oral RIPK1 inhibitor in development for amyotrophic lateral sclerosis (ALS) and multiple …
Patient Dosing Has Begun in Clinical Trial of ALS Therapy, …
May 10, 2022 · Under a collaboration agreement with Denali, Sanofi is leading SAR443820’s Phase 1 and Phase 2 development for ALS and multiple sclerosis (MS) and will co-lead Phase …
Sanofi, Denali ALS Candidate Flops in Mid-Stage Trial
Feb 19, 2024 · Sanofi plans on presenting findings from HIMALAYA at an upcoming medical congress, according to the SEC document. The partners did not reveal their plans for …
ALS / LIVE TODAY FOR TOMORROW
ALS（Amyotrophic Lateral Sclerosis）は、日本語で筋萎縮性側索硬化症（きんいしゅくせいそくさくこうかしょう）と呼ばれる神経の病気で、難病の一つに指定されています。